SEATTLE, WA -- (MARKET WIRE) -- February 12, 2007 -- Targeted Genetics Corporation (NASDAQ: TGEN) provides an update today on its ongoing Phase I/II trial of tgAAC94 in patients with inflammatory arthritis. tgAAC94 is an investigational therapeutic designed to inhibit the activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. The data reported today support the safety and tolerability of a single and repeat intra-articular injections of tgAAC94 to affected joints at doses up to 1x10(13) DNase Resistant Particles per milli-liter (DRP/mL) of joint fluid in subjects with and without systemic TNF-alpha antagonists. The data also continue to suggest that treatment with tgAAC94 may lead to improvements in signs and symptoms of arthritis in injected joints.
